Acomplia is an appetite suppressant which works by acting on brain circuits

The drug company Sanofi Aventis who make the weight loss medication Acomplia say that they have not given up with the possibility of getting FDA approval for the drug in the United States.

Last June Sanofi Aventis suffered a big setback to the plans for Acomplia when the Food & Drug Administration did not recommend that the obesity medication should be approved citing concerns that some people got depressed when using it. Sanofi Aventis however are pushing ahead with new clinical trials and are showing how the medicine can be effective in treating people who suffer from type 2 diabetes.

Sanofi Aventis say that sometime in the year 2009 they will be resubmitting new clinical test results to the Food & Drug Administration for them to review and hopefully then they will approve the drug for sale and marketing in America.

In the meantime Sanofi Aventis are upbeat about the sales of this weight loss medication in Europe where it has been fully approved for over a year now. In Europe since the EMEA gave approval for the drug it has been sold in most European countries being especially popular in Germany where it is estimated that as many as 50,000 people are using it at present.

Acomplia is an appetite suppressant which works by acting on some brain circuits that send signals telling people that they are hungry. Interestingly these brain circuits are identical to the ones that give people “the munchies” when they smoke cannabis. Acomplia however has the opposite effect on these brain circuits to the cannabis and stops people from thinking about food and feeling hungry.

If the Food & Drug Administration gives the Acomplia weight loss drug full approval it will be sold in America under a different name, Zimulti. The American market for weight loss medication is by far the largest market in the world and Sanofi Aventis are therefore very keen to get approval for Acomplia over there.